{"organizations": [], "uuid": "983cb553054c28c3bfa2bc68842ba615c0bfd5bb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "in.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/INhealth\r", "section_title": "Reuters: Health", "url": "https://in.reuters.com/article/us-incyte-study/incytes-combo-therapy-for-skin-cancer-fails-in-late-stage-study-idINKCN1HD1K7", "country": "US", "domain_rank": 408, "title": "Incyte's combo therapy for skin cancer fails in late-stage study", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-06T14:58:00.000+03:00", "replies_count": 0, "uuid": "983cb553054c28c3bfa2bc68842ba615c0bfd5bb"}, "author": "", "url": "https://in.reuters.com/article/us-incyte-study/incytes-combo-therapy-for-skin-cancer-fails-in-late-stage-study-idINKCN1HD1K7", "ord_in_thread": 0, "title": "Incyte's combo therapy for skin cancer fails in late-stage study", "locations": [], "entities": {"persons": [{"name": "arun koyyur", "sentiment": "none"}, {"name": "mrinalini krothapalli", "sentiment": "none"}], "locations": [{"name": "keytruda", "sentiment": "none"}], "organizations": [{"name": "incyte", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "incyte corp", "sentiment": "none"}, {"name": "merck & co", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "(Reuters) - Incyte Corp said on Friday an independent committee concluded that its drug for a type of skin cancer in combination with Merck & Co’s Keytruda failed to meet the main goal in a late-stage study.\nIncyte shares fell 20 percent in premarket trading, while Merck shares were down about 2 percent.\nThe two companies would stop the study as it did not meet the primary goal of improving progression-free survival compared to patients on Keytruda monotherapy.\nMerck’s Keytruda is approved for the treating several forms of cancer, including lung cancer and advanced melanoma.\nThe companies said the study’s second main goal of overall survival was also not expected to reach a statistical significance.\nThe study was evaluating a combination of Incyte’s inhibitor Epacadostat and Merck’s Keytruda for the treatment of metastatic melanoma.\nReporting by Mrinalini Krothapalli; Editing by Arun Koyyur\n ", "external_links": [], "published": "2018-04-06T14:58:00.000+03:00", "crawled": "2018-04-06T15:33:31.012+03:00", "highlightTitle": ""}